- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Diabetes mellitus type 2 (T2DM)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 304KB)
Tirzepatide – November 2024
Tirzepatide; Solution for injection 2.5 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 5 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 7.5 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 10 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 12.5 mg in 0.5 mL vial/pre‑filled pen, Solution for injection 15 mg in 0.5 mL vial/pre‑filled pen; Mounjaro®; Injection 4.17 milligrams per mL (2.5 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 8.33 milligrams per mL (5 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 12.5 milligrams per mL (7.5 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 16.67 milligrams per mL (10 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 20.83 milligrams per mL (12.5 mg per dose) in multi-dose pre-filled pen, 4 doses, Injection 25 milligrams per mL (15 mg per dose) in multi-dose pre-filled pen, 4 doses; Mounjaro® KwikPen®
